173 related articles for article (PubMed ID: 36827901)
1. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.
Li SC; Deng SW; Sun XS; Lan KQ; Guo CY; Lin DF; Liu LT; Liu SL; Mai HQ; Tang LQ
Oral Oncol; 2023 Apr; 139():106336. PubMed ID: 36827901
[TBL] [Abstract][Full Text] [Related]
2. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
3. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.
Wu S; Yuan X; Huang H; Li Y; Cui L; Lin D; Lu W; Feng H; Chen Z; Liu X; Tan J; Wang F
BMC Cancer; 2023 Dec; 23(1):1217. PubMed ID: 38066499
[TBL] [Abstract][Full Text] [Related]
4. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
5. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model.
Sun XS; Xiao ZW; Liu SL; Sun R; Luo DH; Chen QY; Mai HQ
Eur Radiol; 2023 May; 33(5):3682-3692. PubMed ID: 36735041
[TBL] [Abstract][Full Text] [Related]
6. Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy.
He D; Zhang Y; He S; Zhang Y; Dai K; Xu C; Huang Y
Clin Transl Oncol; 2024 May; 26(5):1209-1219. PubMed ID: 38070050
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
8. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.
Tang LQ; Li CF; Li J; Chen WH; Chen QY; Yuan LX; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Zhang L; Guo SS; Liu LT; Guo L; Wu YS; Luo DH; Huang PY; Mo HY; Xiang YQ; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Cao KJ; Qian CN; Guo X; Zeng YX; Mai HQ; Zeng MS
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467665
[TBL] [Abstract][Full Text] [Related]
9. Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases.
Lin C; Sun XS; Liu SL; Li XY; Lu N; Li XL; Tang LQ; Guo L
Cancer Res Treat; 2020 Jul; 52(3):855-866. PubMed ID: 32164051
[TBL] [Abstract][Full Text] [Related]
10. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.
Guo J; Yang Q; Jiang Q; Gu LW; Lin HX; Guo L
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836546
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers.
Lai C; Zhang C; Lv H; Huang H; Ke X; Zhou C; Chen H; Chen S; Zhou L
Cancer Med; 2021 Jun; 10(11):3511-3523. PubMed ID: 33973727
[TBL] [Abstract][Full Text] [Related]
13. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
[TBL] [Abstract][Full Text] [Related]
14. Nomogram Based on Liver Function Test Indicators for Survival Prediction in Nasopharyngeal Carcinoma Patients Receiving PD-1 Inhibitor Therapy.
Liang L; Li Y; Hong Y; Ji T; Chen H; Lin Z
Curr Oncol; 2023 Jul; 30(8):7189-7202. PubMed ID: 37623002
[TBL] [Abstract][Full Text] [Related]
15. Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II-IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort.
Sun XS; Xiao BB; Lin C; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Mar; 9(5):1661-1670. PubMed ID: 31925942
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
[TBL] [Abstract][Full Text] [Related]
17. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
Hu YJ; Lu TZ; Zhang H; Fang M; Chen BJ; Guo QJ; Lin SJ; Feng P; Wang Y; Jiang TC; Gong XC; Pan JJ; Li JG; Xia YF
ESMO Open; 2023 Oct; 8(5):101629. PubMed ID: 37660406
[TBL] [Abstract][Full Text] [Related]
18. The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
Wan Y; Tian L; Zhang G; Xin H; Li H; Dong A; Liang Y; Jing B; Zhou J; Cui C; Chen M; Sun Y; Xie C; Liu L; Shao Y
Radiother Oncol; 2019 Feb; 131():35-44. PubMed ID: 30773185
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
Yeo BSY; Lee RS; Lim NE; Tan E; Jang IJH; Toh HC; Lim CM
Oral Oncol; 2024 May; 152():106786. PubMed ID: 38615584
[TBL] [Abstract][Full Text] [Related]
20. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
